GT Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview

GT Biopharma

24/03/2023 11:44

* GT Biopharma Inc  GTBP.OQ   GTBP.O  is expected to show no
change in quarterly revenue when it reports  results on March 27
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for GT Biopharma Inc is
for a
loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for GT
Biopharma Inc
is $3.5​, above​ its last closing price of $0.62. ​​​

This summary was machine generated March 24 at 11:44 GMT.  All
figures in US dollars  unless otherwise stated